Endosomal proteolysis and MHC class II function

Current Opinion in Immunology

Volumn 10, Issue 1, 1998, Pages 93-102

  Chapman, Harold A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN L; CATHEPSIN S; CHAPERONE; CYSTEINE PROTEINASE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEIN;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; ENDOCYTOSIS; ENDOSOME; ENZYME REGULATION; HAPLOTYPE; NONHUMAN; PROTEIN ASSEMBLY; PROTEIN DEGRADATION; PROTEIN PROCESSING; REVIEW; T LYMPHOCYTE;

EID: 0032005330     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(98)80038-1     Document Type: Article

References (68)

1. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger J, Wiley D. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature. 329:1987;512-518.
2. Cresswell P. Assembly, transport and function and MHC class II molecules. Annu Rev Immunol. 12:1994;259-293.
3. Rudensky AY, Preston-Hurlburt P, Hong SC, Barlow A, Janeway CA Jr. Sequence analysis of peptides bound to MHC class II molecules. Nature. 353:1991;622-627.
4. Riberdy JM, Newcomb JR, Surman MJ, Barbosa JA, Cresswell P. HLA-DR molecules from and antigen-processing mutant cell line are associated with invariant chain peptides. Nature. 360:1992;474-476.
5. Chicz RM, Urban RG, Lane WS, Gorga JC, Stern LI, Vignali DAA, Strominger JL. Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size. Nature. 358:1992;764-768.
6. Campbell RD, Trowsdale J. Map of the human MHC. Immunol Today. 14:1993;349-352.
7. Germain RN. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell. 76:1994;287-299.
8. Wolf PR, Ploegh HL. How MHC class II molecules acquire peptide cargo: biosynthesis and trafficking through the endocytic pathway. Annu Rev Cell Dev Biol. 11:1995;267-306.
9. Roche PA, Cresswell P. Invariant chain association with HLA-DR molecules inhibits immunogenic peptide binding. Nature. 345:1990;615-618.
10. Goldberg AL, Rock KL. Proteolysis, proteasomes, and antigen presentation. Nature. 357:1992;375-379.
11. Hughes AL, Yeager M. Molecular evolution of the vertebrate immune system. BioEssays. 19:1997;777-786.
12. Heemels AL, Ploegh H. Generation translocation, and antigen presentation of MHC class I-restricted peptides. Annu Rev Biochem. 64:1995;463-491.
13. Ojeius DM, Langlade-Demoyen P, Gachelin G, Kourilsky P. Role for MHC class I molecules in selecting and protecting high affinity peptides in the presence of proteases. J Immunol. 152:1994;2798-2810.
14. Lee P, Matsueda GR, Allen PM. T cell recognition of fibrinogen: a determinant on the Aα chain does not require processing. J Immunol. 140:1988;1063-1066.
15. Ghosh P, Amaya M, Mellins E, Wiley DC. The structure of an intermediate in class II maturation: CLIP bound to HLA-DR3. Nature. 378:1995;457-462.
16. Momburg F, Fuchs S, Drexler J, Busch R, Post M, Hammerling Adorini L. Epitope-specific enhancement of antigen presentation by invariant chain. J Exp Med. 178:1993;1453-1458.
17. Demotz S, Matricardi PM, Irle C, Panina P, Lanzavecchia A, Corradin G. Processing of tetanus toxin by human antigen-presenting cells. Evidence for donor and epitope-specific processing pathways. J Immunol. 143:1989;3881-3886.
18. Ojcius DM, Gapin L, Kanelloppoulos JM, Kourilsky P. Is antigen processing guided by major histocompatibility complex molecules? FASEB J. 8:1994;974-978.
19. Davidson HW, Watts C. Epitope-specific processing of specific antigen by B lymphocytes. J Cell Biol. 109:1989;85-92.
20. Deng H, Apple R, Clare-Salzler M, Trembleau S, Mathis D, Adorini L, Sercarz E. Determinant capture as a possible mechanism of protection afforded by major histocompatibility complex class II molecules in autoimmune disease. J Exp Med. 178:1993;1675-1680.
21. d bound peptide to optimize the epitope for recognition by T cells.
22. Berti PJ, Storer AC. Alignment/phylogeny of the papain superfamily of cysteine proteases. J Mol Biol. 246:1995;273-283.
23. Illy C, Quraish O, Wang J, Purisima E, Vernet T, Mort JS. Role of the occluding loop in cathepsin B activity. of special interest J Biol Chem. 272:1997;1197-1202 This study and [24] clarify the structural basis for substrate and inhibitor preferences of cathepsins L and B. The pro-region of both proteins overlies the active-site cleft and prevents substrate entry. In the case of cathepsin L, once the pro-region is removed (mainly by autoactivation at acidic pH) then the cleft is open to substrate entry. In the case of cathepsin B, the occluding loop replaces the pro-region in the cleft of the active enzyme, impairing both substrate entry and inhibition by macromolecular inhibitors such as cystatin C.
24. Coulombe R, Grochulski P, Sivaraman J, Menard R, Mort JS, Cygler M. Structure of human procathepsin L reveals the molecular basis for inhibition by the prosegment. of special interest EMBO J. 15:1996;5492-5503 This study and [23] clarify the structural basis for substrate and inhibitor preferences of cathepsins L and B. The pro-region of both proteins overlies the active-site cleft and prevents substrate entry. In the case of cathepsin L, once the pro-region is removed (mainly by autoactivation at acidic pH) then the cleft is open to substrate entry. In the case of cathepsin B, the occluding loop replaces the pro-region in the cleft of the active enzyme, impairing both substrate entry and inhibition by macromolecular inhibitors such as cystatin C.
25. Musil D, Zucic D, Turk D, Engh RA, Mayr I, Huber R, Popovic T, Turk V, Towatari T, Katunuma N, et al. The refined 2.15Å X-ray crystal structure of human liver cathepsin B: the structural basis for its specificity. EMBO J. 10:1991;2321-2330.
26. Koga H, Mori N, Yamada H, Nishimura Y, Tokuda K, Kato K, Taiji I. Endo- and aminopeptidase activities of rat cathepsin H. Chem Pharm Bull. 40:1992;965-970.
27. Lafuse WP, Brown D, Castle L, Zwilling BS. IFN-gamma increases cathepsin H mRNA levels in mouse macrophages. J Leukocyte Biol. 57:1995;663-669.
28. Linnevers C, Smeekens SP, Broome D. Human cathepsin W, a putative cysteine protease predominantly expressed in CD8+ T-lymphocytes. FEBS Lett. 405:1997;253-259.
29. Jackman HL, Tan F, Schraufnagel D, Dragovic T, Dezso B, Becker RP, Erdos EG. Plasma membrane-bound and lysosomal peptidases in human alveolar macrophages. Am J Respir Cell Mol Biol. 13:1995;196-204.
30. McGuire MJ, Lipsky PE, Thiele DL. Purification and characterization of dipeptidyl peptidase I from human spleen. Arch Biochem Biophys. 295:1992;280-288.
31. + T cell cytotoxic effector function. J Immunol. 158:1997;5200-5210.
32. Vivier I, Marguet D, Naquet P, Bonicel J, Black D, Li CX, Bernard AM, Gorvel JP, Pierres M. Evidence that thymocyte-activating molecules is mouse CD26 (dipeptidylpeptidase IV). J Immunol. 147:1991;447-454.
33. Coombs GS, Dang AT, Madison EL, Corey DR. Distinct mechanisms contribute to stringent substrate specificity of tissue-type plasminogen activator. J Biol Chem. 271:1996;4461-4467.
34. Brachet V, Raposo G, Amigorena S, Mellman I. li controls the transport of major histocompatibility class II molecules to and from lysosomes. of special interest J Cell Biol. 137:1997;51-65 Prior studies (see [4,7]), have reported the distribution of MHC class II molecules in multiple endosomal/lysosomal compartments. Results of this study of MHC class II trafficking in a murine B-cell line indicates that the efficiency of li processing regulates the distribution of MHC class II within cells. This may be directly relevant to more recent work by the same group showing altered MHC class II trafficking as murine dendritic cells mature to antigen presenters [47]. These findings provide yet another role for proteolytic processing of li in regulation of antigen presentation.
35. Sloan VS, Cameron P, Porter G, Gammon M, Amaya M, Mellins E, Zaller DM. Mediation by HLA-DM of dissociation of peptides from HLA-DR. Nature. 375:1995.
36. Sherman MA, Weber DA, Jenson PE. DM enhances peptide binding to class II MHC by release of invariant chain-derived peptide. Immunity. 3:1995;197-205.
37. Fung-Leung W-P, Surh CD, Liljedahl M, Pang J, Leturcq D, Peterson PA, Webb SR, Karlsson L. Antigen presentation and T cell development in H2-M deficient mice. Science. 271:1996;1278-1281.
38. b) lacking H2-M express MHC class II dimers loaded almost exclusively with class II-associated invariant peptide. Analyses of these mice reveal that very few different endosomal peptides are necessary in the thymus for extensive positive and negative T-cell selection.
39. Viville S, Neefjes J, Lotteau V, Dierich A, Lemeur M, Ploegh H, Benoist C, Mathis D. Mice lacking the MHC class II-associated invariant chain. Cell. 72:1993;635-648.
40. Bijlmakers M-E, Benaroch P, Ploegh HL. Mapping functional regions in the lumenal domain of the class II-associated invariant chain. J Exp Med. 180:1994;623-629.
41. Riese RJ, Wolf PR, Bromme D, Natkin LR, Villadangos JA, Ploegh HL, Chapman HA. Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. of special interest Immunity. 4:1996;357-365 This study used a specific inhibitor of cathepsin S in human B cells to demonstrate that cathepsin S rather than cathepsins B, D, or H is required for complete invariant chain degradation to class II-associated invariant peptide and efficient peptide loading.
42. Shi GP, Munger JS, Meara JP, Rich DH, Chapman HA Jr. Molecular cloning and expression of human alveolar macrophage cathepsin S, an elastinolytic cysteine protease. J Biol Chem. 267:1992;7258-7262.
43. West MA, Lucocq JM, Watts C. Antigen processing and class II MHC peptide-loading compartments in human B-lymphoblastoid cells. Nature. 369:1994;147-151.
44. Villadangos JA, Riese RJ, Peters C, Chapman HA, Ploegh HL. Degradation of mouse invariant chain: Roles of cathepsins S and D and the influence of major histocompatibility complex polymorphism. of special interest J Exp Med. 186:1997;549-560 The first study to report studies of li processing in mice with targeted deletion of an endosomal protease (cathepsin D). Much more of this type of approach is forthcoming.
45. Oukka M, Andre P, Turtmel P, Besnard N, Angevin V, Karlsson L, Trans PL, Charron D, Bihain B, Kusmatopoulos K, Lottreau V. Selectivity of the major histocompatibility complex class II presentation pthway of cortical thymic epithelial cell lines. Eur J Immunol. 27:1997;855-859.
46. Mizuochi T, Kasai M, Kokuho T, Kakiuchi T, Hirokawa K. Medullary but not cortical thymic epithelial cells present soluble antigens to helper T cells. J Exp Med. 175:1992;1601-1605.
47. Pierre P, Turley SJ, Gatti E, Hull M, Meltzer J, Mirza A, Inaba K, Steinman RM, Mellman I. Developmental regulation of MHC class II transport in mouse dendritic cells. of special interest Nature. 388:1997;787-791 This study and [48] show that expression of MHC class II complexes by dendritic cells occurs while the cells are immature and endocytically active but is altered by maturation and exposure of cells to inflammatory stimuli. Mature, stimulated dendritic cells have long-lived MHC classII/peptide complexes on their surfaces. This supports the notion that endocytosed protein may in some way persist in young, migratory dendritic cells only to load and be presented as antigen when the cells mature at sites of T-cell accumulation. It will be important to clarify the protease profile of dendritic cells at these various stages of functional maturation.
48. Cella M, Engering A, Pinet V, Pieters J, Lanzavecchia A. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. of special interest Nature. 388:1997;782-786 This study and [47] show that expression of MHC class II complexes by dendritic cells occurs while the cells are immature and endocytically active but is altered by maturation and exposure of cells of inflammatory stimuli. Mature, stimulated dendritic cells have long-lived MHC classII/peptide complexes on their surfaces. This supports the notion that endocytosed protein may in some way persist in young, migratory dendritic cells only to load and be presented as antigen when the cells mature at sites of T-cell accumulation. It will be important to clarify the protease profile of dendritic cells at these various stages of functional maturation.
49. Turk V, Bode W. Human cysteine proteinases and their inhibitors, stefins and cystatins. Katunuma N. Biological Functions of Proteases and Inhibitors. 1994;47-59 Japan Scientific Press, Tokyo Japan.
50. Bevec T, Stoka V, Pungercic G, Dolenc I, Turk V. Major histocompatibility complex class II-associated p41 invariant chain fragment is a strong inhibitor of lysosomal cathepsin L. of special interest J Exp Med. 183:1996;1331-1338 This study and [51] demonstrate that the additional protein sequence present in the p41 form of invariant chain is actually a potent protease inhibitor of cathepsin L. This finding provides a direct link between antigen presentation and proteolysis because prior work [52] has shown that expression of the p41 form of invariant chain promotes presentation of certain antigens much better than the p31 li lacking the inhibitor domain.
51. Fineschi B, Sakaguchi K, Apella E, Miller J. The proteolytic environmental involved in MHC class II-restricted antigen presentation can be modulated by the p41 form of invariant chain. of special interest J Immunol. 157:1996;3211-3215 This study and [50] demonstrate that the additional protein sequence present in the p41 form of invariant chain is actually a potent protease inhibitor of cathepsin L. This finding provides a direct link between antigen presentation and proteolysis because prior work [52] has shown that expression of the p41 form of invariant chain promotes presentation of certain antigens much better than the p31 invariant chain lacking the inhibitor domain.
52. Peterson M, Miller J. Antigen presentation enhanced by the alternatively spliced invariant chain gene product p41. Nature. 357:1992;596-598.
53. Kampgen E, Koch N, Koch F, Stoger P, Heufler C, Shuler G, Romani N. Class II major histocompatibility complex molecules of murine dendritic cells: Synthesis, sialytation of invariant chain, and antigen processing capacity and down-regulated upon culture. Proc Natl Acad Sci USA. 88:1991;3014-3018.
54. Denzin LK, Hammond C, Cresswell P. HLA-DM interactions with intermediates in HLA-DR maturation and a role for HLA-DM in stabilizing empty HLA-DR molecules. of special interest J Exp Med. 184:1996;2153-2165 This study and [68] clarity the forms of MHC class II/invariant chain complexes capable of interacting with HLA-DM. They indicate that while the most abundant complex is with MHC class II/class II-associated invariant peptide, HLA-DM also associates with MHC class II/p 10 (see Figure 1) and empty MHC class II dimers. HLA-DM appears capable of promoting dissociation of the p 10 form of invariant chain from MHC class II in vitro, but clearly the preferred substrate is MHC class II/class II-associated invariant peptide, which is rapidly dissociated in the presence of HLA-DM.
55. Ramachandra L, Kovats S, Eastman S, Rudensky AY. Variation in HLA-DM expression influences conversion of MHC class II α/β class II-associated invariant chain peptide complexes to matutre peptide-bound class II α/β dimers in a normal B cell line. J Immunol. 156:1996;2196-2204.
56. Sette A, Southwood S, Miller J, Appella E. Binding of major histocompatibility complex class II to the invariant chain-derived peptide, CLIP, is regulated by allelic polymorphism in class II. J Exp Med. 181:1995;677-683.
57. Roche N, Chinet TC, Huchon GJ. Allergic and nonallergic interactions between house dust mite allergens and airway mucosa. Eur Respir J. 10:1997;719-726.
58. Lehrer SB, Horner WE, Reese G. Why are some proteins allergenic? Implications for biotechnology. Crit Rev Food Sci Nutr. 36:1996;553-564.
59. Vidard L, Rock KL, Benacerraf B. The generation of immunogenic peptides can be selectively increased or decreased by proteolytic enzyme inhibitors. J Immunol. 147:1991;1786-1791.
60. Rodriguez GM, Diment S. Destructive proteolysis by cysteine proteases in antigen presentation of ovalbumin. Eur J Immunol. 25:1995;1823-1827.
61. Van Noort JM, Van der Drift ACM. The selectivity of cathepsin D suggests an involvement of the enzyme in the generation of T-cell epitopes. J Biol Chem. 264:1989;14159-14164.
62. Kageyama T, Ichinose M, Yonezawa S. Processing of the precursor to neurotensin and other bioactive peptides by cathepsin E. J Biol Chem. 270:1995;19135-19140.
63. Sealy L, Mota F, Rayment N, Tatnell P, Kay J, Chain B. Regulation of cathepsin E expression during human B cell differentiation in vitro. Eur J Immunol. 26:1996;1838-1843.
64. Bromme D, Steinert A, Friebe S, Fittkau S, Wiederanders B, Kirschke H. The specificity of bovine spleen cathepsin S. Biochem J. 264:1989;475-548.
65. Galjart NJ, Morreau H, Willemsen R, Gillemans N, Bonten EJ, d'Asso A. Human lysosomal protective protein has cathepsin A-like activity distinct from its protective function. J Biol Chem. 266:1991;14754-14762.
66. Rawlings ND, Barrett AJ. Dipeptidyl-peptidase II is related to lysosomal pro-X carboxypeptidase. Biochim Biophys Acta. 1298:1996;1-3.
67. Sinigaglia F, Hammer J. Motifs and supermotifs for MHC class II binding peptides. J Exp Med. 181:1995;449-451.
68. Sanderson F, Thomas C, Neefjes J, Trowsdale J. Association between HLA-DM and HLA-DR in vivo. of special interest Immunity. 4:1996;87-96 See annotation for [54]. Subfractionation studies show that HLA-DM is found in association with MHC class II molecules both in the endoplasmic reticulum and in late endosomal/lysosomal compartments. The authors propose that HLA-DM also interacts with invariant chain independently of MHC class II, raising the possibility that invariant chain proteolytic processing may also regulate HLA-DM function.